-
Jade Biosciences (JBIO) files for 3.21M share offering by selling stockholders
-
Clear Street Starts Jade Biosciences (JBIO) at Buy
-
Jade Biosciences (JBIO) files for 16.13M share offering by selling stockholders
-
Jade Biosciences (JBIO) Misses Q3 EPS by 48c
-
Jade Biosciences presents safety data for JADE101 at nephrology conference
-
Jade Biosciences to present JADE101 data at kidney conference
-
BTIG Starts Jade Biosciences (JBIO) at Buy
-
Jade Biosciences unveils JADE201 antibody for autoimmune diseases
-
Jade Biosciences, Inc. (JBIO) Misses Q2 EPS by 55c
-
Jefferies Starts Jade Biosciences (JBIO) at Buy
-
Jade Biosciences (JBIO) Appoints Brad Dahms as Chief Financial Officer
-
Guggenheim Upgrades Jade Biosciences (JBIO) to Buy
-
Stifel Starts Jade Biosciences (JBIO) at Buy
-
TD Cowen Starts Jade Biosciences (JBIO) at Buy

